Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating

瑞穗证券维持Wave Life Sciences(WVE.US)买入评级

moomoo资讯 · 2024/10/17 23:31 · 评级/大行评级

Mizuho Securities analyst Salim Syed maintains $Wave Life Sciences (WVE.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of -2.8% over the past year.

AnalystRecentRatingAutoNews_211469_20241016_1cddd191967f621dbeae6de874d81e23963b649e_1729179007088434_mm_en

Furthermore, according to the comprehensive report, the opinions of $Wave Life Sciences (WVE.US)$'s main analysts recently are as follows:

Recent updates to the financial model for Wave Life Sciences were made following the RestorAATion-2 AATD data release and Takeda's decision not to proceed. Significant alterations include an increased likelihood of success in alpha-1 antitrypsin deficiency and the adjustment of the Huntington's disease program's ownership status, as conveyed to investors.
The firm's increased optimism on Wave Life Sciences is due to the de-risking of key programs and a higher valuation of the pipeline and technology, following encouraging updates across various therapeutic modalities.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

瑞穗证券分析师Salim Syed维持$Wave Life Sciences (WVE.US)$买入评级。

根据TipRanks数据显示，该分析师近一年总胜率为41.4%，总平均回报率为-2.8%。

AnalystRecentRatingAutoNews_211469_20241016_1cddd191967f621dbeae6de874d81e23963b649e_1729179007088434_mm_sc

此外，综合报道，$Wave Life Sciences (WVE.US)$近期主要分析师观点如下：

Wave生命科学的财务模型最近进行了更新，此次更新是基于RestorAATion-2 AATD数据发布以及武田决定不继续的情况。重大的改变包括在alpha-1抗胰蛋白酶缺陷方面成功的可能性增加，以及对亨廷顿病项目所有权状态的调整，这些都已告知投资者。
公司对Wave生命科学的乐观情绪增加是因为主要项目的降低风险以及在各种疗法模式上鼓舞人心的进展，使管道和技术的估值更高。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating

Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating

风险及免责提示

声明